Program Leader
Lina Obeid, MD To define cell signaling pathways leading to proliferation, metastasis, angiogenesis and cell death. These findings will, in turn, lead to the identification of novel targets and therapeutic strategies for the prevention and treatment of cancer Interactions
The Lipid Signaling in Cancer(LCS) Program is one of the most basic research programs within the Hollings Cancer Center (HCC). It is a large and diverse program representing seven departments within the Medical University of South Carolina. The expertise of these nationally and internationally renowned scientists spans the spectrum of cell signaling from structure and function of growth factors to mechanisms of transcriptional activation, G-proteins, receptor and non-receptor tyrosine kinases, sphingolipids and protein effectors of cell signaling pathways. Members of the LCS Program have common interests in signal transduction focused on signaling pathways involved in cell growth, metastases, enhanced tumorigenesis, angiogenesis, tumor suppression and cell death. Specific research efforts of the members of this program are directed toward understanding the role of growth factor and G protein-coupled receptor signaling, lipid mediators of cell signaling, the role of intracellular effectors and protein:protein interactions regulating signaling pathways, protein kinases, and regulatory molecules in controlling cellular proliferation. A number of affinity groups have evolved out of this program, some of which serve as an interface with other research programs in HCC. These include apoptosis, angiogenesis and lipid mediators of cell signaling. Importantly, basic discoveries emanating from activities of these groups have advanced our knowledge on basic mechanisms of cancer pathogenesis and have opened up novel venues for exciting mechanism-based therapeutics. Contact Us
To find out more about this research program, e-mail the Program Leader: Lina Obeid, MD
|
